TMCnet News

AIkido Pharma Inc. Updates Announcement of Webcast Link for the H.C. Wainwright Global Life Sciences Conference (Virtual Event)
[March 04, 2021]

AIkido Pharma Inc. Updates Announcement of Webcast Link for the H.C. Wainwright Global Life Sciences Conference (Virtual Event)


NEW YORK, March 4, 2021 /PRNewswire/ -- AIkido Pharma Inc. (NASDAQ: AIKI) ("AIkido" or the "Company") today announced it will be featured as a presenting company at the H.C. Wainwright Global Life Sciences Conference, a virtual conference held March 9-10, 2021.  The Company will showcase an updated Investor Presentation and discuss some of its new technology. Darrell Dotson, Vice President and General Counsel, of AIkido Pharma Inc. will present for the Company.

The presentation will be available on-demand starting at 7 a.m. ET on Tuesday, March 9, 2021.

The "on demand" webcast of the event will be available for 90 days at https://journey.ct.events/view/acd5b1e7-67aa-4aa4-83c4-3dd0eab43b60

If you are an institutional investor, and would like to attend the Company's presentation, please click on the following link https://hcwevents.com/globalconference/ to register for the conference. 

About H.C. Wainwright

H.C. Wainwright is a full–service investment bank dedicated to providing corporate finance, strategic advisory and related services to public and private companies across multiple sectors and regions.  H.C. Wainwight & Co. also provides research and sales and trading services to institutional investors. According to Sagient Research Systems, H.C. Wainwright's team is ranked as the #1 Placement Agent in terms of aggregate CMPO (confidentially marketed public offering), RD (registered direct offering) and PIPE (private investment in public equity) executed cumulatively since 1998.



About AIkido Pharma Inc.

AIkido Pharma Inc. was initially formed in 1967 and is a biotechnology company with a diverse portfolio of small-molecule anti-cancer therapeutics. The Company's platform consists of patented technology from leading universities and researchers and we are currently in the process of developing an innovative therapeutic drug platform through strong partnerships with world renowned educational institutions, including The University of Texas at Austin and Wake Forest University. Our diverse pipeline of therapeutics includes therapies for pancreatic cancer, acute myeloid leukemia (AML) and acute lymphoblastic leukemia (ALL). In addition, we are constantly seeking to grow our pipeline to treat unmet medical needs in oncology.  The Company is also developing a broad-spectrum antiviral platform that may potentially inhibit replication of multiple viruses including Influenza virus, SARS-CoV (coronavirus), MERS-CoV, Ebolavirus and Marburg virus.


Forward-Looking Statements

Certain statements in this press release constitute "forward-looking statements" within the meaning of the federal securities laws. Words such as "may," "might," "will," "should," "believe," "expect," "anticipate," "estimate," "continue," "predict," "forecast," "project," "plan," "intend" or similar expressions, or statements regarding intent, belief, or current expectations, are forward-looking statements. While the Company believes these forward-looking statements are reasonable, undue reliance should not be placed on any such forward-looking statements, which are based on information available to us on the date of this release. These forward-looking statements are based upon current estimates and assumptions and are subject to various risks and uncertainties, including without limitation those set forth in the Company's filings with the SEC, not limited to Risk Factors relating to its business contained therein. Thus, actual results could be materially different. The Company expressly disclaims any obligation to update or alter statements whether as a result of new information, future events or otherwise, except as required by law.

Contact:
Investor Relations:      
Hayden IR
Brett Maas, Managing Partner
Phone: (646) 536-7331
Email: brett@haydenir.com 
www.haydenir.com

AIkido Pharma Inc.: 
Phone: 212-745-1373
Email: investorrelations@aikidopharma.com 
www.aikidopharma.com 

Cision View original content to download multimedia:http://www.prnewswire.com/news-releases/aikido-pharma-inc-updates-announcement-of-webcast-link-for-the-hc-wainwright-global-life-sciences-conference-virtual-event-301240510.html

SOURCE AIkido Pharma Inc.


[ Back To TMCnet.com's Homepage ]